Feedback / Questions
Bunavail (buprenorphine/naloxone transmucosal) - BDSI
BioDelivery Sciences: Investor Presentation
(Biodelivery Sciences)
-
Mar 17, 2016 -
Anticipated approval for induction claim related to expanded labeling in Q3 2016
Anticipated regulatory
•
Pain
http://bdsi.investorroom.com/presentations_and_events
Mar 17, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious